Aromatase, a cytochrome P450, catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogens. In this study, the regulatory properties of a 696-base pair region, that contains the promoter II and is situated immediately upstream of exon II of the human aromatase gene, were investigated. Chloramphenicol acetyltransferase (CAT) functional studies with DNA segments derived from this genomic region and primer-extension analysis revealed the presence of a second promoter which is functional in adipose stromal cells and in breast cancer cells. Detailed DNase-1 footprinting analysis, DNA mobility shift assays, and CAT functional studies of this genomic region were performed and led to the identification of a segment (B1) that could act as a promoter (probably promoter I.3) in adipose stromal and breast cancer cells. The study revealed further that the B1 region could be divided into two domains which were designated RE1 and RE2. RE1 was found to have the promoter activity, and RE2 was found to regulate the promoter activity of RE1, but in different manners in MCF-7 cells (as an example of breast cancer cells) and in adipose stromal cells. RE2 was found to function as a positive regulatory element in MCF-7 cells and as a negative regulatory element in adipose stromal cells, respectively. DNA mobility shift and UV-cross-linking experiments with BrUrd-substituted B1 fragment and nuclear extracts isolated from two types of cells were performed. The experiments identified DNA-bound proteins with molecular masses around 50 kDa. These findings serve as the basis for further examination of the regulatory mechanism of aromatase expression in human breast cancer and adipose stromal cells.
Estrogens play an important role in breast cancer development. About 60% of premenopausal and 75% of postmenopausal breast cancer patients have estrogen-dependent carcinomas. In estrogen-dependent breast tumors, estrogens induce the expression of peptide growth factors that are responsible for the proliferative responses of cancer cells (1, 2) . Aromatase, a cytochrome P450, synthesizes estrogens by catalyzing three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogenic steroids. Since aromatase is the enzyme responsible for the synthesis of estrogens, and estrogens have a major effect in the development of breast cancer, an abnormal expression of aromatase in breast cancer cells and/or surrounding adipose stromal cells may have a significant influence in breast tumor maintenance and growth in breast cancer patients.
James et al. (3) reported that aromatase activity when measured in vitro was found to be higher in breast tumors than in the fat next to the tumor or in normal breast fat. In addition, Miller and O'Neill (4) found a highly significant correlation between aromatase activity and the presence of tumors in individual quadrants of breast tissues. Recently, using quantitative PCR 1 analysis, adipose stromal cells surrounding the cancer cells have also been reported to contain aromatase mRNA at a higher level than adipose stromal cells in noncancerous areas (5) . Although Bradlow (6) has estimated that the contribution of in situ aromatization to the estrogen pool may be small, Reed et al. (7, 8) reported that in some breast tumors, in situ formation of estrogens can make an important contribution to the estrogen content of breast cancer cells. Kitawaki et al. (9) reported that by converting androgen to estrogen (at physiological concentrations), the endogenous aromatase enzyme in the MCF-7 breast cancer cells (estrogen receptor (ER) positive cells) stimulated DNA synthesis, and the stimulation was abolished by the administration of aromatase inhibitors. In 1993, using a stable aromatase-expressing MCF-7 cell line (expressing aromatase at a level 10 times that of the untransfected MCF-7 cell line (10)), androgen-dependent cell growth was observed (11) . In addition, tumors were grown in nude mice inoculated with the aromatase transfected MCF-7 cells together with Matrigel (12) . The tumor growth was accelerated by injections of androstenedione. These cell-culture and nudemouse experiments using aromatase transfected MCF-7 cells demonstrate, in a direct fashion, that aromatase expressed in breast cancer cells can play a role in stimulating the growth of tumors.
Since it is thought that tumor aromatase can play a role in stimulating the growth of breast tumors, it is important to understand how its expression is regulated in tumors. An understanding of the regulatory mechanism for the expression of aromatase in breast tumors will provide us with information concerning the role of aromatase in tumors and, potentially, a modality to treat estrogen-dependent breast cancer by controlling the estrogen biosynthesis in estrogen-producing cells. It is known that a complex mechanism is involved in the control of human aromatase expression. Six exons I have been reported. As indicated in Fig. 1 , primer extension experiments have identified exons I.1 and I.2, exons I.3 and I.4, and exon PII 1 The abbreviations used are: PCR, polymerase chain reaction; RT-PCR, reverse transcription-polymerase chain reaction; ASC, adipose stromal cells; CAT, chloramphenicol acetyltransferase; CRE, cAMP response element; C-0, pCAT TM -Control; E-0, pCAT TM -Enhancer; E-259bp, pCAT-E-259bp; E-0.65kb, pCAT-E-0.65kb; E-259-162bp, pCAT-E-259-162bp; E-259-0.4kb, pCAT-E-259-0.4kb; ER, estrogen receptor; pBo, pCAT TM -Basic; GRE, glucocorticoid response element; RACE, rapid amplification of cDNA ends; bp, base pair(s); kb, kilobase(s). using mRNA isolated from placenta, adipose stromal cells, and ovary, respectively (13) (14) (15) (16) (17) . Exon I.4 has also been found in aromatase mRNA in skin fibroblasts (15) . Another exon I, I.5, has also been suggested (18) . It is thought that aromatase expression in these tissues is driven by the promoters situated upstream from these exons I, providing tissue-specific controls of aromatase expression. We recently detected the presence of aromatase mRNA in human breast tumors by reverse transcription-polymerase chain reaction (RT-PCR) techniques. 2 PCR products, using oligonucleotide primers derived from exon II of the human aromatase gene, were detected in 67 of 70 tumor specimens. We also applied RT-PCR techniques to determine the exon I usage in breast tumor aromatase mRNA using appropriate exon I primers. Our studies have revealed that aromatase mRNA isolated from breast tumors contains mainly exons PII and I.3, suggesting that promoters II and I.3 are the major promoters driving aromatase expression in breast cancer and in the surrounding adipose stromal cells. This has been confirmed by RT-PCR analysis of mRNA isolated from an adipose stromal cell line (that was used in this study) and four breast cancer cell lines (MCF-7, T-47D, SK-BR-3, and MDA-MB-231). Exons PII and I.3 were again found to be the major exons I in aromatase mRNA in these cell lines.
Primer-extension and 5Ј-RACE (rapid amplification of cDNA ends) experiments show exons PII and I.3 to be situated within the 696-bp region immediately upstream of exon II (14, 16) . Promoters II and I.3 have been suggested to be situated approximately 25 bp upstream from these exons I. In a previous paper (19) , results from the chloramphenicol acetyltransferase (CAT) functional studies (on aromatase-expressing cells (i.e. MCF-7, JAR, OVCAR-3, and skin fibroblasts)) were presented to show that the region immediately upstream of the exon II can function as a promoter, probably promoter II. Recently, we extended our functional study of this promoter to include two additional breast cancer lines (T-47D and SK-BR-3) and also adipose stromal cells. The results suggest the presence of an additional promoter which is located upstream from exon II, but is different from the one identified previously in this laboratory (19) . DNA deletion, DNA mobility shift, DNase-1 footprinting, and extensive CAT expression analyses on this genomic region demonstrate the presence of a promoter (probably I.3) situated upstream from the previously identified promoter. This newly identified promoter is found to be regulated by an immediately adjacent region. Additionally, it is shown that the regulatory interaction between these sequences is different in adipose stromal cells and breast cancer cells, such as MCF-7 cells.
EXPERIMENTAL PROCEDURES
Materials-T4 kinase, T4 DNA ligase, and restriction endonucleases were obtained from Boehringer Mannheim, New England Biolabs, Inc., and Life Technologies, Inc. Radiolabeled nucleotides were from DuPont NEN. [ C]chloramphenicol; specific radioactivity, 55 mCi/mmol) was from Amersham. DNA sequencing kits were from United States Biochemical Corp. The CAT expression vectors were from Promega.
Cell Culture-MCF-7, T-47D, and SK-BR-3 cell lines were from ATCC (Rockville, MA). Human adipose stromal cells were generated at the Dept. of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco. Human adipose stromal cells were established after collagenase (Worthington Biochemical Co., Freehold, N.J.) digestion of subcutaneous adipose tissue by the method of Killinger et al. (20) and kindly provided by Drs. P. Siiteri and J. Murai.
MCF-7 cells, derived from a breast adenocarcinoma, were maintained in minimum essential medium Earle's salts containing 10% fetal calf serum. T-47D cells, derived from a breast ductal carcinoma, were grown in RPMI 1640 medium, in the presence of 10% fetal calf serum and 0.2 IU of insulin/ml. SK-BR-3 cells, also derived from a human adenocarcinoma, were maintained in McCoy's 5a medium containing 10% fetal calf serum. Adipose stromal cells were grown in DME-H21 containing 20% calf serum, penicillin G (10,000 units/ml), streptomycin (10 mg/ml), and fungizone (250 g/ml). Skin fibroblasts were maintained in Dulbecco's modified Eagle's high glucose medium with 10% fetal calf serum.
Primer Extension Analysis-Primer extension analysis was conducted according to standard procedures (21) . An antisense 34-mer oligonucleotide complimentary to a region near the 5Ј end of exon 1.3 of the human aromatase cDNA (5Ј-GGTAGAGTCTCAGGTTCCTTTAG-ACGCT-TGGTC-3Ј) was synthesized and end-labeled with [␥-32 P]ATP. This probe was hybridized to 20 g of total RNAs isolated from MCF-7 cells and human skin fibroblasts at 65°C for 90 min. The product was extended with avian myeloblastosis virus reverse transcriptase and then analyzed by electrophoresis on a 6% polyacrylamide sequencing gel and autoradiography. Sequencing ladders generated with the same antisense oligonucleotide as primer were run in adjacent lanes to determine the size of primer extension products.
CAT Expression Plasmids-Three sets of CAT expression plasmids were generated and used to investigate the regulatory properties of the 696-bp genomic fragment (see Fig. 2 ). A set of four CAT expression plasmids containing different sizes of genomic fragments derived from the 5Ј-flanking region of exon I.3 were prepared, i.e. pBo 0.31kb, pBo 0.23kb, pBo 0.07kb, and pBo 0.04kb (see Fig. 4A ). These genomic fragments were prepared using the PCR method and were subcloned into the CAT expression plasmid, pCAT TM -Basic (pBo), which lacks both a promoter and an enhancer element. Transfection experiments using these CAT expression plasmids confirmed the presence of a promoter, i.e. I.3, upstream from exon I.3.
CAT expression plasmids containing B1, RE1, or RE2 (see Fig. 4B ) were used in the second part of this study. These plasmids were generated in the following manner. Single-stranded oligonucleotides with the sequences corresponding to that of B1, RE1, and RE2 were synthesized and annealed to their complementary strands. For the convenience of subcloning, HindIII sites were introduced at both ends of each oligonucleotide. These oligonucleotides were (only sense strands are shown): B1, 5Ј-AGCTTCTTATAATTTGGCAAGAAATTTGGCTTTA-3Ј; RE1, 5Ј-AGCTTCTTATAATTTGGCAAA-3Ј; RE2, 5Ј-AGCTTCAA-GAAATTTGGCTTTA-3Ј. The double-stranded oligonucleotides were inserted into HindIII site of pCAT TM -Basic in various copy numbers and directions. The copy numbers and directions of the oligonucleotides inserted into the CAT expression plasmid were confirmed by DNA sequencing.
Additional CAT expression plasmids used in this study are described below. As indicated in the previous publication (19) , a 259-bp fragment containing the immediate upstream region of exon II is thought to contain a promoter because a promoter activity is detected when CAT functional studies were performed with cells transfected with a CAT plasmid containing this fragment, pCAT-E-259bp (i.e. E-259bp). The studies also revealed that a negative regulatory element is present upstream from the promoter because the CAT activity is minimal in cells transfected with a CAT expression plasmid containing this region, such as pCAT-E-0.65kb (i.e. E-0.65kb). The restriction map of the 696-bp human aromatase genomic fragment are shown in Fig. 2A .
Furthermore, pCAT TM -Control (C-0) (Promega) contains SV40 promoter and SV40 enhancer sequences, resulting in strong expression of CAT activity in transfected cells. pCAT TM -Enhancer (E-0) is a CATexpression plasmid containing an SV40 enhancer element alone and allows for testing the promoter function of a gene fragment. As indicated in the paper by Wang and Chen (19) , the promoter function of the 259-bp fragment can only be observed by ligating into E-0. pCAT-E259bp (E-259bp), as indicated above, is a plasmid generated by ligating the 259-bp aromatase promoter fragment into E-0. pCAT-E-0.65kb (E-0.65kb) is a plasmid generated by ligating the 646-bp fragment containing the promoter and the silencer element into E-0. pCAT-E-259-162bp (E-259-162bp) was derived by ligating the 162-bp silencer fragment upstream of the 259-bp fragment. pCAT-E-259-0.4kb (E-259-0.4kb) was derived by ligating the 434-bp BglII restriction fragment (see Fig. 2A ) upstream of the 259-bp fragment. E-259-0.4kb is different 2 from E-0.65kb by having the additional 43 bases upstream of the EcoRI site (see Fig. 2A ). Diagrams of E-259bp, E-259-162bp, E-259-0.4kb, and E-0.65kb are shown in Fig. 2C .
Transfection Experiments-DNA transfections in MCF-7, T-47D, and SK-BR-3 cells were carried out using the DEAE-dextran transfection method (22) . The transfection experiments were performed 20 to 24 h after seeding approximately 4 ϫ 10 5 cells per 25-cm 2 flask using 10 g of plasmid DNA per sample. The DNA was introduced to the cells through incubation in the presence of DEAE-dextran (150 g/ml medium). After incubation with the cells for 3 h, the medium containing DEAE-dextran/DNA was removed. Cells were shocked in 10% dimethyl sulfoxide (in 1 ϫ phosphate-buffered saline) and grown again in proper media. In each transfection experiment, cotransfection with a small quantity of the plasmid pRSV/GCZ, which contains the ␤-galactosidase gene, and under the control of the RSV promoter, was used to normalize the transfection efficiency.
Adipose stromal cells are very fragile and cannot stand the DEAEdextran treatment. The transfection experiments with these cells were carried out using Lipofectin TM following the manufacturer's protocol (Life Technologies, Inc.). The time of the Lipofectin TM /DNA treatment was 6 h.
Chloramphenicol Acetyltransferase and ␤-Galactosidase Assays-After transfection with CAT expression plasmids, cells were incubated for 72 h and then harvested and disrupted by freeze-thawing. The protein concentrations of the extracts were determined by the Bradford method (23). CAT assay was performed using an equal amount of protein from each sample. CAT activity was determined according to the procedure described by Gorman et al. (24) . For quantification, spots corresponding to acetylated and nonacetylated [
14 C]chloramphenicol were cut out from the TLC plate and the radioactivity was determined by scintillation counting. The percent conversion for each sample was calculated. The percent conversions in T-47D and SK-BR-3 cells transfected with C-0 were 79% and 48%, respectively, indicating that CAT was expressed in these cells in an effective manner. The percent conversion in MCF-7 cells transfected with C-0 was similar to that reported in a previous publication. For evaluation of the expressed CAT activity, the percent conversion associated with C-0 transfected samples was used as an activity of 100%, unless indicated otherwise. The percent conversion in adipose stromal cells transfected with the plasmid E-259-0.4kb, i.e. the samples with the highest CAT activity in the study involving the 259-bp region, was 12%. A higher CAT activity was measured in adipose stromal cells transfected with pBo RE1 (see Fig. 7 ). The low percent conversion for transfected adipose stromal cells may result from a low transfection efficiency. We are examining additional transfection methods for improving the transfection efficiency for the studies with adipose stromal cells. While the transfection efficiency is low, we are confident regarding the results obtained with adipose stromal cells since we have performed each analysis three to six times with different batches of cells and consistent results were obtained.
␤-Galactosidase levels were determined by measuring an increase in optical density at 410 nm using O-nitrophenyl-␤-D-galactopyranoside as a substrate according to Rosenthal (25) except that samples were incubated for 6 h.
Nuclear Extract Preparations-Nuclear extracts from each of the cultured cells were prepared according to the method of Kingston (26) with a slight modification. Cells were harvested and washed twice with PBS. Pellets were resuspended in 10 volumes of buffer A (300 mM sucrose, 10 mM Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EGTA) and homogenized by 20 strokes of a Kontes all glass Dounce homogenizer (A pestle). Buffer A and all buffers described below contained 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, and 2 g/ml each of pepstatin, leupeptin, and antipain. After centrifugation at 4,000 rpm for 5 min, the pellets were resuspended in 10 volumes of buffer B (10 mM Hepes, pH 7.9, 400 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EGTA, and 5% glycerol) and were dounced 20 times with a B pestle. Homogenates were mixed for 30 min on rotator wheel in the cool room and then centrifuged at 15,000 ϫ g for 30 min. Supernatants were collected and dialyzed for 4 h against 50 volumes of buffer C (20 mM Hepes, pH 7.9, 0.1 mM EDTA, 75 mM NaCl, and 20% glycerol). Dialysates were centrifuged at 15,000 ϫ g for 15 min and supernatants were quence of this region. The TATA boxes in promoter 1.3 and promoter II and the potential regulatory elements are underlined. RE1 region was protected from DNase-1 digestion by the nuclear proteins from MCF-7 cells, and the RE2 region was protected by the proteins from adipose stromal cells. C, diagrams of E-259bp, E-259-162bp, E-259-0.4kb, and E-0.65kb.
FIG. 2.
Structure of the upstream region of exon II of the human aromatase gene. A, restriction map. B, the nucleotide se-stored at Ϫ70°C until used in gel-shift assays and footprinting analyses.
DNA Mobility Shift Analysis-The 696-bp fragment (Fig. 2 ) from the upstream region of exon II of aromatase gene was digested with AluI and BglII. The resulting 162-bp fragment was isolated and subcloned into the SmaI site of pUC19 plasmid. The 162-bp fragment was excised from the vector using EcoRI and XbaI and end-labeled with [␥-32 P]ATP and T4 kinase. This radioactive fragment was used for the mobility shift assay. Gel-shift assays were done as described in Singh et al. (27) . Briefly, 5 g of nuclear extract was incubated with 4000 cpm of 32 Plabeled probe at room temperature for 30 min in 15 l of a mixture containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM dithiothreitol, 4% (v/v) glycerol, and 0.1 mg/ml poly(dIdC). The reaction mixture was electrophoresed on 4% acrylamide:bisacrylamide (74:1) gel with 0.5 ϫ TBE at 10 V/cm at room temperature. Gels were dried and autoradiographed. For competition experiments, the conditions used for binding of the nuclear factors to each probe were the same as those described above except that the appropriate amounts of the unlabeled DNA fragments and poly(dI-dC) were supplemented in the binding reaction mixture as a specific and a nonspecific competitor DNA, respectively. For immunological analysis, 5 g of nuclear extract was incubated 1 h at 4°C with 5 g of rabbit polyclonal IgG against c-Myc, TFIID, or p53 (Santa Cruz Biotechnology, Santa Cruz, CA). Extract-antibody mixtures were then used for gel-shift assays.
DNase-1 Footprinting Analysis-Probes for footprinting were labeled by EcoRI digestion of pUC19 -280bp and pUC19 -162bp followed by 5Ј-labeling of the coding strand with [␥- 32 P]ATP and T4 kinase, and the noncoding strand with [␣-
32 P] dNTP and Klenow fragment. Probes were then excised with XbaI digestion, separated on polyacrylamide gels, extracted, and precipitated.
The binding reaction conditions were the same as those described above for DNA mobility shift analysis. The appropriate amount of nuclear extracts were incubated with 10,000 cpm of 32 P-labeled probes at room temperature for 30 min in 15 l of reaction mixture containing 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 1 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM dithiothreitol, 4% glycerol, and 0.1 mg/ml poly(dI-dC). One-fourth to one unit of DNase-1 in 20 l of Tris buffer (10 mM, pH 7.5) containing CaCl 2 (5 mM) and MgCl 2 (10 mM) were then added, and the incubations continued for 1-5 min at room temperature. The action of DNase-1 was then stopped by adding Tris buffer (10 mM, pH 7.5) containing 100 mM NaCl, 20 mM EDTA, 1% SDS, and 50 g/ml yeast tRNA. The reaction mixtures were extracted with phenol:chloroform:isoamyl alcohol (25: 24:1) and precipitated with ethanol. The reaction products were separated on 6% polyacrylamide sequencing gels and subjected to autoradiography. The sequencing of the probes was performed as described by Maxam and Gilbert (28) and were loaded adjacent to the DNase-1 cut samples.
Deletion Mutagenesis-The B1 region was divided into two fragments, RE1 and RE2, through the oligonucleotide synthesis. The sequence of B1, RE1, and RE2 are as follows (only sense strands are shown): B1, 5Ј-CTTATAATTTGGCAAGAAATTTGGCTTT-3Ј; RE1, 5Ј-CTTATAATTTGGCAA-3Ј; RE2, 5Ј-CAAGAAATTTGGCTTT-3Ј. A mutated B1 region (MuB1) was also synthesized (5Ј-CTTATAATTTG-GCAAATTTGGCTTT-3Ј), with a 3-base deletion from 4-base spacer between repeat sequences (underlined) in B1 region. Two complementary oligonucleotides for each fragment were annealed, and the resulting double-stranded fragments were either subcloned into pCAT TM -Basic vector or used as specific competitors in gel-shift assays.
UV-cross-linking Studies-The UV-cross-linking experiments were performed as described by Chodosh et al. (29) with some modifications. The BrUrd-substituted oligonucleotides for B1 fragment were synthesized by DNA synthesis laboratory at the City of Hope. Doublestranded, BrUrd-substituted B1 fragment was end-labeled with [␥-
32 P]ATP with T4 kinase and used as probe in UV-cross-linking experiments. In these experiments, 15 g of nuclear extract were incubated with 1 ϫ 10 5 cpm of 32 P-labeled, BrUrd-substituted B1 and 2.5 g of poly(dI-dC) for 30 min at room temperature in 20 l of the same binding buffer as described for DNA mobility shift experiments. The mixtures were irradiated for 6.5 min under a UV transilluminator at 254 nm and an intensity of 120,000 microwatts/cm 2 (UVC.515 ultraviolet multilinker, Ultra-Lum, Inc., Carson, CA) at a distance of 5 cm from the UV source. The mixtures were then electrophoresed on a 10 -20% gradient SDS-polyacrylamide gel, and the gels were dried and autoradiographed.
RESULTS

Characterization of Promoter I.3 by DNA Deletion Analysis-
The transcriptional initiation site of exon I.3 was determined by sequencing clones from 5Ј-RACE cDNA libraries prepared from mRNA isolated from human adipose stromal cells and skin fibroblasts (16, 17 ) (see Fig. 2B ). We have confirmed these results by primer extension analysis using RNA isolated from MCF-7 cells (Fig. 3) . A TATA box-like sequence is situated 15 bp upstream from the start site and has been suggested to be the promoter I.3 (16) . In this study, we intended to demonstrate the presence of a promoter I.3 by promoter functional analysis. A series of different sizes of genomic fragments derived from the 5Ј-flanking region of exon I.3 were prepared using the PCR method. These fragments were subcloned into the CAT expression plasmid, pBo, i.e. a CAT plasmid without a promoter or an enhancer element.
The CAT activity in MCF-7 cells, SK-BR-3 cells, adipose stromal cells (ASC), and skin fibroblasts that were transfected with pBo 0.31kb, pBo 0.23kb, pBo0.07kb, or pBo0.04kb was measured, and the results are shown in Fig. 4B . The structures of the reporter constructs are shown in Fig. 4A . While the results suggest the presence of negative regulatory element(s) in the 5Ј-region of the 0.23-kb fragment and positive regulatory element(s) in the 5Ј-region of the 0.07-kb fragment, the 0.04-kb region (containing the TATA box-like sequence) is thought to contain the basic promoter since similar CAT activities were found in all four types of cells transfected with pBo 0.04kb. The following experiments were then designed to characterize the promoter, i.e. promoter I.3, in the 0.04-kb (or the 40 base pair) region.
DNase-1 Footprinting Analysis of the 280-bp Fragment-We decided to further define this promoter region by DNase-1 footprinting analysis. DNase-1 footprinting analysis was carried out on the 280-bp AluI restriction fragment (see Fig. 2A ) using nuclear extracts from MCF-7 and from adipose stromal cells. Using nuclear extracts from MCF-7 cells, a region of protection from base pair 282 to 296 (5Ј-CTTATAATTTG-GCAA-3Ј, indicated in Fig. 2B) was observed (Fig. 5) . This region was termed RE1. The proteins in the nuclear extract from adipose stromal cells protected the adjacent sequences from base pairs 294 to 309 (5Ј-CAAGAAATTTGGCTTT-3Ј). This region was termed RE2. There is a 3-bp overlap between RE1 and RE2. Together, RE1 and RE2 were termed binding region 1 (B1) (5Ј-CTTATAATTTGGCAAGAAATTTGGCTTT-3Ј). B1 is a part of the 0.04-kb region described above. It should be noted that RE1 contains the TATA box-like sequence (bold- G, A, T, and C) . The sizes of the extended products, as determined from the known fragment sizes of the DNA sequence ladders, is indicated on the right. face). DNase-1 footprinting analysis was also performed on the 162-bp Alu/BglII restriction fragment (see Fig. 2A ), and identical footprinted regions were found (results not shown).
Functional Characterization of the B1 Region-Having defined the RE1, RE2, and B1 regions through DNase-1 footprinting analysis, these regions were subcloned separately into pCAT TM -Basic expression plasmid to check whether they have any promoter function and/or play a role in the regulation of promoter-driven transcription. Double-stranded oligonucleotides corresponding to RE1, RE2, and the complete B1 sequence were chemically synthesized and ligated into the CAT TM -Basic plasmid, pBo. Adipose stromal cells and MCF-7 cells were transfected with these plasmids, and CAT activity in the transfected cells were determined. The results from CAT transient expression (by measuring CAT activity) in MCF-7 and adipose stromal cells showed that RE1 activated the transcription of the CAT gene, and this transcriptional activation activity appears to be orientation-dependent as well as copyindependent (see Fig. 6 ). These results and those obtained from DNA deletion analysis led us to conclude that there is a promoter present in the RE1 region. It is probably the promoter I.3 as suggested by Mahendroo et al. (16) and confirmed by us through a direct promoter functional analysis. A comparison study on the level of CAT activity in MCF-7 and adipose stromal cells transfected with B1-, RE1-, and RE2-containing CAT expression plasmids showed that whereas RE1 could act independently as a promoter, its action was affected by the presence of RE2 (Fig. 7) . When RE1-and B1-containing CAT expression plasmid were transfected into MCF-7 cells, the CAT activity of B1-containing lines showed a 2-fold increase over that of RE1-containing cells. Therefore, in MCF-7 cells, the presence of RE2 enhanced the promoter function of RE1. Conversely, in adipose stromal cells, RE2 suppressed the promoter of RE1 by 9-fold and therefore functioned as a negative regulatory element. The fact that the regulatory activities of these constructs differed in the cell lines is very interesting in that extracts from these cell lines also showed different patterns of DNase-1 protection (as described previously). Furthermore, RE2 acts neither as an enhancer nor a negative regulatory element in a noncancerous breast cell line HBL-100 because the CAT activity in HBL-100 cells transfected with CAT plasmids containing RE1 and B1 showed no difference (data not shown). Fig. 7 also shows that pBo 162-bp transfected cells have a lower CAT activity than pBo B1-transfected cells, supporting our previous finding that there is a silencer element in the 162-bp region (19) and indicating that the silencer also suppresses the function of the promoter in B1.
Mutagenesis of B1-The above experiments showed that the promoter activity of RE1 was affected by the presence of RE2. The RE1 and RE2 both contain the sequence (5Ј-AATTTGGC-3Ј) forming a direct repeat. A double-stranded oligonucleotide corresponding to the entire B1 but with a 3-base pair deletion between the two repeats (5Ј-CTTATAATTTGGCAAATTTG-GCTTT-3Ј) was synthesized and termed MuB1. MuB1 was cloned into the pCAT TM -Basic vector. There was no CAT activity detected in the cell extract from both MCF-7 and adipose stromal cells transfected with this CAT construct (Fig. 7) . This result was interesting in that the deletion construct still contains the entire RE1 sequence which would have been expected to have promoter activity. Therefore, not only does RE2 have an effect on the promoter activity of RE1, but also its orientation with respect to RE1 is critical.
DNA Gel Mobility Shift Analysis-DNA mobility shift analysis was performed to determine whether a DNA-protein complex involving specific interactions between regulatory factors and B1 could be resolved. Gel-shift assays were performed using the 162-bp fragment as a probe bound to nuclear extracts from MCF-7 cells. Under the conditions described, two DNAprotein complexes were resolved (Fig. 8) . The formation of these complexes could be competitively inhibited by the addition of either cold 162-bp fragment or B1 but not by the addition of cold poly(dI-dC). Therefore, the observed interaction was sequence-specific and involved the B1 region. Furthermore, the complex formation could be inhibited by the addition of cold RE1 but significantly less effectively by the addition of RE2. In fact, in the footprinting analysis, a very weak protection of RE2 could be observed when using MCF-7 nuclear extracts (see Fig.  5 ). In the DNA gel mobility shift analysis, the competition of RE2 for the 162-bp fragment-protein interaction could be observed only because the RE2 fragment was present at a concentration of 25 times that of the 162-bp probe. Since MuB1 still contains the entire RE1, it is not unexpected that the formation of the 162-bp fragment-protein complexes can be reduced by the addition of MuB1 (with a concentration of 25 times that of the 162-bp probe). However, MuB1 was not as effective as B1 or RE1 in competing with the 162-bp fragment for protein binding, possibly again due to a change in the orientation of RE2 with respect to RE1. The binding orientation of the protein(s) to MuB1, compared with B1, must be significantly modified, resulting in a total loss in the ability to drive CAT expression (as indicated above).
As mentioned above, RE1 contains a TATA box sequence. We have performed experiments in which anti-TFIID polyclonal antibodies were used to challenge protein-DNA interactions before electrophoresis in gel-shift assays. Addition of polyclonal antibody against TFIID resulted in a reduction of the intensity of the sequence-specific complex (Fig. 9, lane 6) indicating the presence of TFIID in this complex. As a control, the addition of anti-c-Myc, anti-p53, and bovine serum albumin did not result in the reduction of the intensity of the DNA-protein complexes (Fig. 9, lanes 3, 4, and 5) .
Specific DNA-protein complexes were also observed when DNA mobility shift analysis was performed on the 162-bp fragment with nuclear extracts isolated from adipose stromal, HBL-100, T-47D, SK-BR-3, JAR, or OVCAR-3 cells. The results are being carefully evaluated.
UV-cross-linking Study of the Proteins Binding to the B1 Region-UV (ultraviolet) light can cause covalent bond formation between radioactive labeled DNA and proteins that are in close contact with the DNA and enable us to visualize the bound proteins. The study revealed that several nuclear proteins with molecular masses around 50 kDa bind to B1 (Fig.  10) . Furthermore, both RE1 and RE2 were able to effectively compete with B1 for binding proteins in the nuclear extracts from adipose stromal cells, but RE1 was significantly more effective than RE2 in competing with nuclear proteins isolated from MCF-7 cells. Since nuclear proteins isolated from MCF-7 cells mainly bind to RE1 as indicated by DNase-1 footprinting experiments, it is expected that RE2 cannot compete effectively with B1 for binding proteins in this UV-cross-linking study. However, the results are different from those seen in the DNase-1 footprinting experiments in which extracts from adipose stromal cells did not protect the RE1 region. The UVcross-linking results show that RE1 binding is involved in the protein-DNA complex formed with adipose stromal extracts. The absence of protection in the footprinting experiments may be due to a lower RE1 binding affinity in adipose stromal extracts as compared with MCF-7 extracts and therefore below the limits of detection. The interaction between RE1 and proteins in adipose stromal extracts may be enhanced by the UV light-induced covalent bond formation. This may also explain why RE2 is able to partially compete for the binding of protein(s) in MCF-7 nuclear extract to B1 in the UV-cross-linking study. The UV-cross-linking study also revealed that there were nuclear proteins in HBL-100 cells, probably TATA boxbinding proteins, that could bind to B1 (Fig. 10C) . RE1, but not RE2, was capable of competing with B1 for protein binding. The latter results agree also with that obtained with DNA mobility shift analysis, indicating that no protein binds to the RE2 region in HBL-100 cells which do not express aromatase.
DISCUSSION
Detailed DNase-1 footprinting analysis, DNA mobility shift assays, and CAT functional studies of a 696-base pair region in the human aromatase gene led to the identification of a segment (B1) that could act as a promoter (probably promoter I.3) in adipose stromal and breast cancer cells. The investigation revealed further that the B1 region could be divided into two domains which were designated RE1 and RE2. RE1 was found to have the promoter activity, and RE2 was found to regulate the promoter activity of RE1, but in different manners in MCF-7 cells and in adipose stromal cells. RE2 was found to function as a positive regulatory element in MCF-7 cells and as a negative regulatory element in adipose stromal cells, respectively. It is our hypothesis that the RE2 binding factor(s) found in MCF-7 and adipose stromal cells have different binding affinities or characteristics which result in different effects on the transcriptional machinery assembled at the TATA box in RE1 (i.e. I.3). There are at least two possible mechanisms involving these regulatory factors. RE2 binding protein(s) could be different in the two types of cells. In MCF-7 cells, RE2-binding protein(s) facilitate the binding of the TATA box-binding proteins to the TATA box when it binds the RE2, and in this way that the transcription activity of RE1 is enhanced. In adipose stromal cells, RE2-binding protein(s) binds to the RE2 region strongly enough that a clear footprint was detected in the RE2 region with nuclear extracts from adipose stromal cells. Since there is a 3-bp overlap between RE1 and RE2, the protein(s) bound to the RE2 would mask the RE1 to a certain degree and might negatively regulate RE1 promoter function through a competitive mechanism. It is also possible that the same protein(s) is involved in regulating the promoter activity in both types of cells. In the latter situation, a much more complex mechanism may be involved to provide two different effects in two types of cells. For the CAT functional studies, we also observed that pBo RE2-transfected adipose stromal cells has a CAT activity similar to that in pBo B1-transfected cells (Fig. 7) . We cannot yet explain this result in an adequate P-labeled, BrUrd-substituted B1 probe as described in the text in the absence or presence of nonradiolabeled oligonucleotides, B1, RE1, and RE2 as specific competitors or with poly(dI-dC) as nonspecific competitor. The samples were then irradiated with UV light to cross-link the nuclear proteins with probe and the molecular weights of the cross-linked proteins were determined by 10 -20% gradient SDS-PAGE and autoradiography. fashion.
These current findings are very interesting, but far from providing a clear explanation of the results obtained from characterization of this genomic region in our and other laboratories. For example, the determined properties of the new promoter (promoter I.3) and downstream regulatory region (RE2) cannot yet explain the results of CAT function studies with the larger genomic fragments. In a previous study (19) , CAT functional studies were performed to show that the region immediately upstream of the exon II can function as a promoter. However, the promoter function of this region is repressed in several types of aromatase-expressing cells (i.e. MCF-7, JAR, OVCAR-3, and skin fibroblasts) by the inhibitory function of a silencer element situated upstream of this promoter. Recently, CAT functional studies were extended to two additional aromatase-expressing breast cancer lines, SK-BR-3 and T-47D. CAT activity in SK-BR-3 cells transfected with the plasmid E-259bp was 40 Ϯ 9% (data not shown) of that in cells transfected with the plasmid C-0, indicating that the 259-bp fragment can behave as a promoter in these cells although its activity was lower than that when transfected into MCF7, OVCAR-3, and JAR cells (99, 136, and 81% of the control activity, respectively (19) ). Since the CAT activity in SK-BR-3 cells transfected with the plasmid E-0.65kb (5 Ϯ 1% of the control activity) was very similar to that in cells transfected with the plasmid E-0 (4% of the control activity), the silencer element in the 0.65-kb fragment is functional in SK-BR-3 cells and possibly suppresses both promoters II and I.3.
CAT activity in T-47D cells transfected with E-259bp was 119 Ϯ 6% (data not shown) of that in cells transfected with the plasmid C-0, again showing promoter activity in this fragment. Additionally, it was found that the CAT activity in T-47D cells transfected with the plasmid E-0.65kb was 34 Ϯ 12% of the control activity, significantly higher than that of the cells transfected with the plasmid E-0 (10 Ϯ 4% of the control activity). This result implied that either the silencer element in the 0.65-kb fragment was only partially functional in T-47D cells.
However, the CAT activity in adipose stromal cells transfected with the plasmid E-259bp was found to be the same as that in cells transfected with the negative control plasmid E-0 (Table I ), indicating that the promoter in the 259-bp fragment is not functional in adipose stromal cells. CAT activity was seen when the adipose stromal cells were transfected with the plasmid E-0.65kb (265 Ϯ 14% of that in cells transfected with E-0). In a second series of experiments, adipose stromal cells were transfected with plasmid E-0, E-259bp, E-259 -162bp, or E-259 -0.4kb. Among this set of transfected cells, only cells transfected with E-259 -0.4kb had a significant level of CAT activity (324 Ϯ 100% of that in cells transfected with E-0) ( Table I) . Together with the above results, this suggests that promoter I.3 is used to drive aromatase expression in adipose stromal cells.
Recently, primer-specific RT-PCR performed in our laboratory to determine the usage of different exons I in breast tumor specimens and breast cancer and adipose stromal cell lines revealed that promoters II and I.3 are the major promoters driving aromatase expression in breast tumors and cell lines. 2 This is not totally agreeable with our results of CAT function studies described above. The results obtained so far would indicate that the control and regulation of the transcription of the human aromatase gene is very complicated. Other regulatory cis elements and trans factors must exist for regulating aromatase expression in breast cancer and adipose stromal cells.
On the other hand, this and a previous study (19) from this laboratory are very important in that they have identified two promoters, probably II and I.3, present within 696 bp upstream from exon II of the human aromatase gene, through a direct promoter functional analysis. This will set as the basis for further examination of the regulatory mechanism of aromatase expression involving these promoters. The results obtained so far suggest that promoter I.3 is a stronger promoter than promoter II. The promoter I.3 function can be investigated by ligating it (i.e. RE1 or B1) into pCAT TM -Basic plasmid. On the other hand, the promoter II function can only be investigated by ligating it (i.e. the 259-bp fragment) into pCAT TM -Enhancer plasmid. However, at this time, we cannot eliminate the possibility of the presence of negative regulatory element(s) in the 259-bp region that suppresses the promoter II function.
It is possible that a number of regulatory elements (either positive or negative regulatory elements) are involved in controlling the function of these promoters. This and the previous study by Wang and Chen (19) have revealed that the function of both promoters II and I.3 can be repressed by the proposed silencer element present in the 162-bp region; E-259-162bp-transfected cells are always found to have a lower CAT activity than E-259bp-transfected cells, and pBo 162bp-transfected cells are found to have a lower CAT activity than pBo B1-transfected cells. However, E-259-0.4kb-transfected adipose stromal cells were found to have a CAT activity significantly higher than E-259 -162bp-transfected cells (Table I) , suggesting that the region upstream from promoter I.3 (see Fig. 2 , A, B, and C) contains positive regulatory element(s) that may enhance the function of promoter I.3 and/or promoter II in driving aromatase expression in adipose stromal cells. Recent footprinting analysis of the EcoRI/AluI 272-bp fragment, that is upstream from the 162-bp segment, have revealed footprints at regions with consensus sequences as CRE, GRE, and AP-1. The DNA deletion analysis shown in Fig. 4 suggest the presence of an enhancer element in the 5Ј-end of 0.07-kb fragment and a CRE-like sequence is found in this region. It has been suggested that aromatase expression in adipose stromal cells can be induced significantly by cAMP and phorbol esters in the absence of serum (30) . In the case of breast cancer cells such as MCF-7 cells, E-0.65kb-transfected cells have a lower activity than E-259bp-transfected cells. These results suggest that in order to drive aromatase expression, promoters II and I.3 (the major promoters as suggested by the RT-PCR analysis) have to be up-regulated by positive regulatory elements present outside of this genomic region.
The findings of multiple promoters in the human aromatase gene would explain the complexity of the regulation mechanism of aromatase expression in different tissues.
While we are studying the genomic region immediately upstream from exon II of the human aromatase gene, excellent studies have been performed to characterize the promoter I.1 a Each experiment was performed in triplicate. The CAT activity in cells transfected with E-0 was taken as 100%. Experimental detail is described under "Experimental Procedures." region of the human aromatase gene (31) , and a characterization of promoter I.4 region of the human aromatase gene has also been initiated (32) . In addition, a detailed analysis of a cAMP regulation of aromatase expression in rat ovary (33, 34) and promoter I.4 region of the human aromatase gene (35) have been carried out. As indicated in the introduction, aromatase is the enzyme synthesizing estrogen, and therefore plays a critical role in estrogen-dependent breast cancer development. These studies from our and other laboratories should shed some light on the control mechanism of aromatase expression at a transcriptional level, leading to new strategies to control estrogen synthesis in breast cancer cells or other estrogenproducing cells in breast cancer patients.
